Stock info Gilead Sciences | Filter  Basic-Info

Stock: Gilead Sciences (US Tech), ISIN: US3755581036

Last Price 73.09 Max Price 86.70
Min Price 71.58 1 Year return 0.66
Sector Health Care Subsector Biotechnology
Annual report 2020

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Gilead Sciences' mission is to advance the care of patients suffering from life-threatening diseases worldwide. In addition to Gilead Sciences' marketed products, Gilead Sciences has a clinical, preclinical and research pipeline focused on developing anti-infectives. Gilead Sciences’ stocks are traded in New York and the company is a component of the NASDAQ 100-index (ISIN: US3755581036/ Symbol: GILD).

Loading...

Contact info:Street: Foster City, CA 94404Zip Code: CA 94404City: Foster CityCountry: USAPhone: (650) 5743000Email: investor_relations@gilead.comWebsite: www.gilead.comCEO: John C. MartinCFO: Robin L. Washington

Sector Review Gilead Sciences

Loading...
Year Turnover Total sector Market share
2019 22,449 141,925 15.82 %
2020 24,689 170,231 14.50 %
2021 27,305 252,886 10.80 %
2022 27,281 238,500 11.44 %
2023 0 0 0.00 %

Advice Gilead Sciences

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
November 03, 2020 Morgan Stanley Gilead Sciences Hold 67.00 6.66 %
September 15, 2020 RBC Capital Markets Gilead Sciences Hold 82.00 23.73 %
August 19, 2020 Jefferies & Co. Gilead Sciences Buy 78.00 19.82 %
August 19, 2020 Robert W. Baird Gilead Sciences Buy 70.00 10.66 %
August 19, 2020 Credit Suisse Gilead Sciences Hold 70.00 10.66 %
May 04, 2020 KBC Securities Gilead Sciences Hold 82.00 23.73 %
April 30, 2020 ABN AMRO Gilead Sciences Hold 83.00 24.65 %
April 20, 2020 BMO Capital Markets Gilead Sciences Hold 78.00 19.82 %
April 20, 2020 Wells Fargo Gilead Sciences Hold 87.00 28.11 %
February 06, 2020 Cowen and Company Gilead Sciences Buy 80.00 21.82 %
February 06, 2020 Raymond James Gilead Sciences Buy 80.00 21.82 %
February 06, 2020 RBC Capital Markets Gilead Sciences Hold 86.00 24.30 %
February 06, 2020 Jefferies & Co. Gilead Sciences Buy 76.00 14.34 %
February 05, 2020 KBC Securities Gilead Sciences Buy 82.00 20.61 %
January 09, 2020 RBC Capital Markets Gilead Sciences Hold 89.00 30.39 %
October 28, 2019 RBC Capital Markets Gilead Sciences Hold 67.00 9.27 %
October 28, 2019 Raymond James Gilead Sciences Buy 81.00 24.95 %
October 28, 2019 BMO Capital Markets Gilead Sciences Hold 81.00 24.95 %
August 01, 2019 JP Morgan Gilead Sciences Buy 85.00 26.42 %
August 01, 2019 Credit Suisse Gilead Sciences Hold 67.00 -4.61 %
August 01, 2019 Raymond James Gilead Sciences Buy 86.00 18.50 %
August 01, 2019 BMO Capital Markets Gilead Sciences Hold 82.00 14.52 %
July 15, 2019 Wells Fargo Gilead Sciences Buy 88.00 11.94 %
May 28, 2019 Goldman Sachs Gilead Sciences Sell 60.00 -4.23 %
May 24, 2019 Citigroup Gilead Sciences Buy 78.00 19.82 %
May 23, 2019 Citigroup Gilead Sciences Buy
May 21, 2019 Credit Suisse Gilead Sciences Hold 70.00 -6.80 %
May 07, 2019 Raymond James Gilead Sciences Buy 83.00 4.65 %
May 07, 2019 Leerink Swann & Company Gilead Sciences Hold 78.00 19.82 %
May 07, 2019 JP Morgan Gilead Sciences Buy 87.00 9.03 %
May 07, 2019 RBC Capital Markets Gilead Sciences Hold 91.00 13.03 %
February 13, 2019 RBC Capital Markets Gilead Sciences Hold 84.00 18.48 %
February 13, 2019 Wells Fargo Gilead Sciences Buy 68.00 -0.71 %
February 13, 2019 Citigroup Gilead Sciences Hold 75.00 8.69 %
February 13, 2019 Raymond James Gilead Sciences Buy 85.00 19.44 %
February 12, 2019 KBC Securities Gilead Sciences Hold 82.00 16.49 %
February 06, 2019 Raymond James Gilead Sciences Buy 90.00 26.92 %
February 06, 2019 Morgan Stanley Gilead Sciences Hold 83.00 20.76 %
February 05, 2019 RBC Capital Markets Gilead Sciences Hold 89.00 25.44 %
February 05, 2019 KBC Securities Gilead Sciences Hold 87.00 23.72 %



News Gilead Sciences

FDA puts partial clinical hold on Gilead's magrolimab + azacitidine studies

Gilead Sciences (NASDAQ:GILD) announces that the FDA has placed a partial clinical hold on studies evaluating the combination of magrolimab plus azacitidine due to an apparent imbalance in suspected unexpected serious adverse reactions (SUSARs) between study...

Gilead and Merck ink collaboration agreement for Keytruda/Trodelvy breast cancer study

Gilead Sciences (NASDAQ:GILD) has entered into a clinical trial collaboration and supply agreement with Merck KGaA (NYSE:MRK) to evaluate the efficacy of Trodelvy in combination with Keytruda as a first-line treatment for certain patients with triple-negative...

Gilead and Novo Nordisk expand collaboration in NASH therapeutics

Gilead Sciences (NASDAQ:GILD) and Novo Nordisk (NYSE:NVO) have announced an expansion of their clinical collaboration in non-alcoholic steatohepatitis ('NASH"). The two companies have agreed to conduct a Phase 2b study to investigate the safety and efficacy...

Gilead Sciences now in top highest dividend yields in America

Investors in Gilead Sciences can expect a huge dividend payment. Based on the recent analysts' consensus the stock now has one of the highest dividend returns of the American market. Per share the analysts anticipate on a dividend of 2,7 USD per share. The dividend...

Analysts expect over 2020 rising revenue Gilead Sciences, quite high dividend

For this year Gilead Sciences's revenue will be around 24,2 billion USD. This is according to the average of the analysts' estimates. This is slightly more than 2019's revenue of 22,45 billion USD. Historical revenues and results Gilead Sciences plus estimates...

Annual reports Gilead Sciences

2017 2018 2019 2020 2021

Profile Gilead Sciences

Gilead Sciences

(US3755581036)/ GILD

Gilead Sciences has located her head office Foster City. Gilead Sciences mainly operates in the biotech sector. John C. Martin manages the company as a CEO. The CFO of Gilead Sciences the company is Robin L. Washington. The global biotech companies gained around 59 percent over the period 2006-2016. Since 2011 the sector is 70 percent higher and over the past year minus 59 percent.

The past year was a good year for Gilead Sciences investors

Over the last 12 months, that were loss-making period for the investors in Gilead Sciences, the stock lost around 28 percent. Over the period from December 2011 till December 2016 the stock rose on average 280 percent. Gilead Sciences's revenues between 2011 and 2015 were very volatile through the time and moved between 9,7 billion dollars and 32,64 billion dollars. Gilead Sciences's net incomes between 2011 and 2015 were very volatile and moved between 2,79 billion dollars and 18,11 billion dollars.

Gilead Sciences paid out dividends in the past 5 years. Over the past 5 years the stock delivered an average dividend return of 1,29 percent.

Gilead Sciences had about 7000 thousand employees at the end of 2015.

Gilead Sciences' balance mostly consists of equity

At the end of 2015 the American company had a balance sheet of around 51,84 billion dollars. The total debt of the biotech company was at the end of 2015 33,31 billion dollars, which equals around 64,25 percent of the total balance sheet. At the end of 2016 the American company was traded with a price/earnings-ratio of around 8. So investors paid 8 times the company's 2015's EPS. Based on the classical stock valuation theories the American stock can be seen as a value stock.

The biotech company's market capitalization (the number of shares outstanding times the market value) equaled around 139,71 billion dollars. At the end of 2015 around 1,42 billion stocks were listed.

On this page you can find all Gilead Sciences's financial reports. More information about Gilead Sciences can be found it's website. .


Results Gilead Sciences

Results
2015
2016
2017
2018
2019
2020
Revenue
32,639
30,390
26,107
22,127
22,449
24,689
Costs
14,531
16,889
21,479
16,672
17,063
24,566
Profit
18,108
13,501
4,628
5,455
5,386
123
Margin of profit
55.48
44.43
17.73
24.65
23.99
0.50
ROI
97.70
71.48
22.64
25.51
23.91
0.68

Balance Gilead Sciences

Balance
2015
2016
2017
2018
2019
2020
Equity
18,534
18,887
20,442
21,387
22,525
18,202
Debt
33,182
38,090
49,841
42,288
39,102
50,205
Total assets
51,716
56,977
70,283
63,675
61,627
68,407
Solvency
35.84
33.15
29.09
33.59
36.55
26.61
Cash
14,608
11,895
25,510
30,089
24,352
7,408
Cashflow
21,250
17,047
11,898
8,400
9,144
8,168
Employees
0
0
0
0
0
Revenue per employee
0.0
0.0
0.0
0.0
0.0
Cashflow / Debt
0.64
0.45
0.24
0.20
0.23
0.16

Details Gilead Sciences

Details
2016
2017
2018
2019
2020
Price
101.19
71.61
71.64
62.55
64.98
Eps
9.94
3.51
4.17
4.22
0.10
Price/earnings-ratio
10.18
20.40
17.18
14.82
730.90
Dividend
1.84
2.08
2.28
2.52
2.72
Dividend %
1.82 %
2.90 %
3.18 %
4.03 %
3.72 %
Payout %
0.19
0.59
0.55
0.60
27.20
Book value
14.45
15.63
16.68
17.79
14.52
Market to book
0.14
0.22
0.23
0.28
0.20
Cashflow per stock
13.04
9.10
6.55
7.22
6.51
Stocks
1,307
1,308
1,282
1,266
1,254
Market Cap
132.255.33
93.665.88
91.842.48
79.188.30
91.654.86

Dividend Gilead Sciences


Price info Gilead Sciences

Date
Price
22 Mar 2024
73.09
18 Mar 2024
73.69
15 Mar 2024
74.21
12 Mar 2024
75.32
11 Mar 2024
75.12
09 Mar 2024
75.12
07 Mar 2024
72.63
01 Mar 2024
72.10
29 Feb 2024
72.70
27 Feb 2024
72.95
22 Feb 2024
73.20
21 Feb 2024
72.04
20 Feb 2024
71.58
15 Feb 2024
73.04
14 Feb 2024
73.53
13 Feb 2024
74.45
09 Feb 2024
73.80
08 Feb 2024
74.42
07 Feb 2024
77.72
06 Feb 2024
76.71
05 Feb 2024
76.96
01 Feb 2024
78.26
31 Jan 2024
78.62
30 Jan 2024
79.07
27 Jan 2024
79.52
25 Jan 2024
79.53
24 Jan 2024
79.48
23 Jan 2024
78.43
16 Jan 2024
86.38
11 Jan 2024
84.50